Katharina Rothe

Vancouver, BC V6T1Z3, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia.

Journal: Cells
Published: August 15, 2025

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.

Journal: Leukemia
Published: June 29, 2022

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.

Journal: Blood
Published: June 12, 2020

Puncta intended: connecting the dots between autophagy and cell stress networks.

Puncta intended: connecting the dots between autophagy and cell stress networks.

Journal: Autophagy
Published: June 09, 2020

Loss of m1acp3Ψ Ribosomal RNA Modification Is a Major Feature of Cancer.

Loss of m1acp3Ψ Ribosomal RNA Modification Is a Major Feature of Cancer.

Journal: Cell reports
Published: November 07, 2019

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.

Journal: Blood
Published: October 07, 2019

Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.

Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.

Journal: Cell stem cell
Published: April 05, 2019

Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions.

Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions.

Journal: International journal of molecular sciences
Published: December 18, 2018

Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?

Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?

Journal: Autophagy
Published: August 29, 2018

Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia".

Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia".

Journal: Science translational medicine
Published: August 12, 2018

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia.

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia.

Journal: Science translational medicine
Published: May 31, 2017

CuboCube: Student creation of a cancer genetics e-textbook using open-access software for social learning.

CuboCube: Student creation of a cancer genetics e-textbook using open-access software for social learning.

Journal: PLoS biology
Published: March 08, 2017
Showing 1-12 of 17

Last Updated: 09/26/2026